The price of Ozempic is a meaningless phrase
By JOHN SAMARAS Ask what Ozempic costs. The honest answer runs from $25 a month…
The price of Ozempic is a meaningless phrase
By JOHN SAMARAS Ask what Ozempic costs. The honest answer runs from $25 a month to $1,100 a month, and every number in that range is real, published, and defensible. A phrase that covers a forty-four-fold spread is not a price. It is a fog, and patients make four-figure annual decisions inside it. I run…
Physician Competition: Entry and Substitution
That is the title of a Journal of Economic Literature article by Gottlieb and Nicholson (2026). Here is a Q&A summary of their article. What are the defining features of physician competition? The authors argue that competition in the physician market is a two-stage process: “First, potential physicians compete to enter medical school and then…
‘The Moat is No Longer Technological’: How Digital Health Fundraising Changed in H1
Digital health funding hit $7.4 billion in the first half of 2026, with megadeals absorbing nearly half of all capital. As AI becomes table stakes, founders and investors say the real differentiator is now domain expertise rather than technology. The post ‘The Moat is No Longer Technological’: How Digital Health Fundraising Changed in H1 appeared…
Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer
Celcuity drug Revtorpyk is now approved for advanced cases of the most common type of breast cancer that do not harbor a certain mutation. The intravenously infused medicine is first in a new drug class that addresses a pathway associated with many cancers. The post Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type…
Neko Health Secures $700M to Support US Expansion
Neko’s Series C round was co-led by Lightspeed Venture Partners and O.G. Venture Partners, with participation from Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum and BDT & MSD. The post Neko Health Secures $700M to Support US Expansion appeared first on MedCity News.
A Profile of Dual-Eligible Individuals
Approximately 12 million people are enrolled in both Medicare and Medicaid, referred to as dual-eligible individuals. This brief examines the demographic, socioeconomic, and health characteristics of dual-eligible individuals compared with Medicare beneficiaries without Medicaid.
Five Key Facts About Spending and Enrollment for People with Medicare and Medicaid (Dual-Eligible Individuals)
This issue brief analyzes provides a profile of enrollment and spending on dual-eligible individuals, drawing on new analysis of data on chronic conditions to show how higher rates of chronic conditions contribute to higher average spending among this population.
Answers at the Speed of Thought: Healthcare Analytics in the Era of Agentic AI
We are moving into an era where we can finally converse with our data. We can ask, “Why are denials spiking in Region X?” or “Show me the safety profile of this cohort,” and receive an answer, not a spreadsheet. The post Answers at the Speed of Thought: Healthcare Analytics in the Era of Agentic…
The Measurement Problem Behind Two Decades of Neurology Trial Failures
The FDA now treats continuous, real-time data sharing as a regulatory direction of travel rather than a theoretical future. The neurology field should pay close attention. The post The Measurement Problem Behind Two Decades of Neurology Trial Failures appeared first on MedCity News.
Off the Radar: How Unapproved AI Is Complicating Healthcare Cyber Risk
You cannot secure what you cannot see, and right now, healthcare organizations are accumulating hidden cyber liabilities with every keystroke. The post Off the Radar: How Unapproved AI Is Complicating Healthcare Cyber Risk appeared first on MedCity News.
